gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · XLOHealthcarePharmaceuticals

Xilio Therapeutics, Inc. Common Stock (XLO)

$8.71+0.35%
Close Nov 4, 2026 · split-adjusted
Nov 4, 2026$8.71▼ 22.41% in range
Nov 4, 2025Low $7.16 · High $99.98Nov 4, 2026
What changed · written from our data
As of Nov 4, 2026

Xilio Therapeutics closed at $8.71 on Nov 4, up 0.35%, 91.3% below its 52-week closing high. Volume of 11.8K shares was 0.74× its 20-day average (below normal).

Split-adjusted performance: -3.2% over one month, +10.3% over six months, -26.8% over one year.

In the quarter ended Jun 30, 2026, revenue was $18.69M, up 131.2% from a year earlier, with a net margin of -34.1%.

Short interest was 400.3K shares at the Oct 15 settlement, down 2.4% from the prior report (10.1% of float, 41.2 days to cover).

Market cap$57.3M6.6M shares
Revenue · quarter$18.7M+131.2% YoY
Diluted EPS$-0.33—
P/E · TTM—P/S 0.9×
Net margin-34.1%Gross 100.0%
Dividend yieldNone
52-week range7.16 – 99.98−91.3% from high
Volume11.8K0.74× 20-day avg
Volatility · 60d38.3%Annualised
Short % of float10.1%41.2 days to cover
Net cash$136.0MCash $136.0M
Next earnings—Not scheduled
Split-adjusted performance
1W +8.7%1M −3.2%3M −6.0%6M +10.3%YTD −2.8%1Y −26.8%3Y −70.4%5Y −96.1%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum76
Revenue growth87
Net margin50
Value (low P/E)—
Size33

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →
Shares short400.3K−2.4% vs prior
Days to cover41.2Settled Oct 15
% of float10.1%
Short vol. 10d37.1%of daily volume

Closest peers by size in Pharmaceuticals

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
XLOXilio Therapeutics$8.71+0.35%+10.3%+131.2%−34.1%—$57.3M
RNTXRein Therapeutics$0.6587−1.32%−43.7%———$56.8MCompare
CTORCitius Oncology$0.5470−0.55%−39.8%—−597.4%—$57.9MCompare
HRTXHeron Therapeutics$0.2986+4.88%−77.2%+1.3%−14.6%—$56.7MCompare
NMADNomad Power Solutions$3.60+2.27%————$58.0MCompare
CLNNClene$4.10+8.75%−42.7%+233.3%−14915.6%—$58.3MCompare
RFLRafael Holdings$1.07−0.93%−14.4%−30.3%−3760.7%—$55.8MCompare
ONCYOncolytics Biotech$0.4248+8.92%−53.8%———$55.7MCompare
RNXTRenovoRx$1.31+1.55%+47.2%+115.4%−320.2%—$59.1MCompare

News about Xilio Therapeutics

All news →
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire Inc. · Oct 2, 2026NeutralXilio Therapeutics Announces Pricing of Underwritten OfferingGlobeNewswire Inc. · Feb 12, 2026▲ Positive

Quick answers

What does Xilio Therapeutics do?
Xilio Therapeutics Inc is a clinical-stage biotechnology company focused on discovering and developing masked immuno-oncology (I-O) therapies to improve outcomes for people living with cancer. Leveraging its clinically validated masking technology and capabilities, the company develops I-O therapies designed to selectively activate within the tumor microenvironment to achieve durable efficacy without the severe side effects associated with systemically active I-O agents.
What is XLO's market cap?
$57.31M, based on the Nov 4 close of $8.71.
Does Xilio Therapeutics pay a dividend?
No regular cash dividend has been paid in the last year.
How much of XLO is sold short?
400.3K shares, 10.1% of float, as of Oct 15, 2026.
What sector is XLO in?
Healthcare, in the Pharmaceuticals industry.

About Xilio Therapeutics

Xilio Therapeutics Inc is a clinical-stage biotechnology company focused on discovering and developing masked immuno-oncology (I-O) therapies to improve outcomes for people living with cancer. Leveraging its clinically validated masking technology and capabilities, the company develops I-O therapies designed to selectively activate within the tumor microenvironment to achieve durable efficacy without the severe side effects associated with systemically active I-O agents. Its integrated biology and protein engineering approach enables the design and development of potent masked biologics that are activated by tumor-specific proteases.

HQ: Waltham, MA76 employeesListed Oct 22, 2021xiliotx.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology